Guiding structural heart interventions to increase safety and efficacy

Try TAVIguide


FEops HEARTguide proprietary array of products use advanced computer simulations to provide CLINICIANS and VALVE MANUFACTURERS first-ever insights into the interaction between valve and specific patient anatomy – preoperatively.

Such insights have tremendous power to accelerate research and development of novel valve-based solutions, as well as ultimately improve clinical outcomes in real-world hospital settings.

Try TAVIguide

computer simulation

Using routine preoperative imaging data FEops creates a patient-based computer simulation model that allows to predict the interaction between a device and a patient's unique anatomy. This presents a prime opportunity to integrate valve design with patient-specific testing, and to do that virtually, cost-effectively and in a clinically meaningful way.

Our first product is the CE-marked TAVIguide.

Try TAVIguide

The TAVIguide

TAVIguide predicts the interaction between the TAVI device and the specific patient, combining routine preoperative CT imaging with advanced computer simulations.

Try it and get up to 3 TAVIguide analyses free of charge.

Try TAVIguide

is easy


Rocatello et al. Patient-Specific Computer Simulation to Elucidate the Role of Contact Pressure in the Development of New Conduction Abnormalities After Catheter-Based Implantation of a Self-Expanding Aortic Valve. Circ Cardiovascular Interv 2018; 11(2) More info

Karady J. Transcatheter mitral valve replacement in mitral annulus calcification - "The art of computer simulation" J Cardiovasc Comput Tomogr; 2018; 17 More info

Schultz et al. Patient-specific image-based computer simulation for the prediction of valve morphology and calcium displacement after TAVI with the Medtronic CoreValve and the Edwards SAPIEN. EuroIntervention 2016; 11 1044-1052More info

de Jaegere et al. Patient-Specific Computer Modelling to Predict Aortic Regurgitation After Transcathether Aortic Valve Replacement. JACC Card Intv 2016; 9 (5) 508-512 More info


Case reports
& testimonials

  • Coming soon!

    There are no case reports available yet.

  • Dr Peter de Jaegere

    EMC, Rotterdam, NL

    I believe this technology will have an important clinical implication. It will allow the selection of both the size and position of the valve for a particular patient (tailored medicine), which will increase the safety and efficacy of TAVI.

  • Dr Azeem Latib

    San Rafaele, Milano, IT

    Ideally, as TAVI becomes standard of care even in low and intermediate risk patients, it would be great to take the guess-work out – to be able to simulate what is going to happen when you put the valve into that anatomy.

  • Dr Mark Monaghan

    King’s College, London, UK

    In order to make structural heart procedures more predictable, computational modeling is likely to have a critical role to play.  FEops have successfully developed technology that simulates the interaction between implanted devices and various cardiac structures.  We view this as a very exiting development in interventional cardiology.

  • Dr Carlos Ruiz

    Hackensack University Medical Center, New York, USA

    Pre-operatively simulating different scenarios of the intervention will undoubtedly play a key role in further reducing complications for structural heart interventions.

  • Dr Ronak Rajani

    Guy’s and St Thomas’, London, UK

    FEops are leading the way in image segmentation and computer modelling. With an emphasis on structural intervention, new solutions are being developed to enable clinicians to better plan for their procedures and to predict outcomes more robustly than historical geometric data alone.



FEops nv

Technologiepark 19
9052 Gent

+32 9 292 80 30

Management Team

Since February 2018, Isabelle Decroos is our Chief Operating Officer. She has over 15 years of international financial management experience in various industries, including 5 years in the lifescience and biopharmaceutical industry. Prior to joining FEops, Isabelle worked at Argenx SE, where she was part of the team that led the company through its succesful IPO on Nasdaq. Isabelle has a Master degree in Commercial Engineering from the University of Antwerp and an MBA degree from the Vlerick Business School.

Nico has worked in the cardiovascular medical device space for more than 2 decades. He joined FEops in June 2018. Prior to FEops, he worked at St Jude Medical/Abbott where he was the EMEA marketing director responsible for the Cardiac Rhythm Management portfolio. Nico held also different strategic and commercial roles at Boston Scientific, Guidant and Servier.

Matthieu transformed FEops from a small academic spin-off into a fast-growing venture capital backed gazelle in the medtech sector. He completed his degree in Engineering at the University of Ghent in 2002 and gained his PhD in 2008 for his research on cardiovascular device and procedure modeling. In 2009 he followed the general management program ‘Technology Transfer’ at Vlerick Leuven Gent Management School. Matthieu is author of several high-impact scientific publications.

Christian has a long track record of success in the cardiovascular device industry. His health care industry experience spans three decades with always a strong focus on cardiovascular medical devices. He has held multiple roles within the structural heart space in different key market players, leading structural heart clinical trials. Developing educational programs as EMEA VP Education and Head of therapy development EMEA. Christian is bringing substantial expertise to FEops’ vision to become the game-changer in the way transcatheter structural heart procedures are planned as well as supporting the design of such devices.

Peter is a co-founder of FEops, and holds the position of Chief Technology Officer (CTO). He is internationally recognized for his groundbreaking work in using computer simulations to evaluate cardiovascular implants and procedures. Under his supervision, the TAVIguideTM technology has been transformed from an innovative idea into a CE marked techology. Peter received a PhD in biomedical engineering from Ghent University.

Board of Directors

Rob Michiels was elected as a member of the Company's Board of Directors in 2016.  He is a 30plus-year veteran of the US medical device industry, both in corporate positions and as a serial startup entrepreneur.  He most recently served as Chief Executive Officer of CardiAQ™ Valve Technologies, a venture funded start-up developing Transcatheter Mitral Valve Implantation and which was acquired by Edwards Lifesciences late 2015.  He previously served as President and Chief Operating Officer (COO) of CoreValve; and as President and COO of InterVentional Technologies.  He helped drive both companies from cardiovascular start-ups to established market leaders, developing and marketing new and innovative interventional technologies which have strong synergies to the FEops story.  Rob Michiels is also a founding partner of CONSILIUM Associates, a medical device market research company active in identifying, funding and greenhousing start-up technologies. Fluent in English, French and Dutch, he holds a bachelor's degree in economics from Antwerp University in Belgium and a Masters in business administration (MBA) from Indiana University

Alexandra Tolia is Senior Investment Manager at PMV, where she directs investments in innovative Life Sciences ventures. Since 2011 she has served as board member in several biotech companies, including eTheRNA, Multiplicom, FEops, iTeos Therapeutics and Apitope. Prior to PMV she led the investment strategy at Hunza Ventures, where she was instrumental in establishing the fund's biotech portfolio in Europe and the US. For over a decade before joining the investment industry, Alexandra built an international scientific career, pioneering drug development initiatives in neurodegeneration and cardiovascular diseases, and managing key alliances between academia and the pharmaceutical industry. Alexandra holds a PhD in Medical Sciences from the University of Leuven, a degree in Management from the Solvay Brussels School of Economics and Management and is the author of several high-impact scientific publications.

Marc Lambrechts is Senior Investment Manager at Capricorn Venture Partners NV. Marc’s investment interests are related to technology fusion and more specifically ICT, digital healthcare, IoT and nanotechnology. Marc was in charge of the successful investments in a.o. Enfocus, FillFactory and Punch Powertrain. He serves on the board of FEops, Bluebee and Leuven.Inc Prior to joining Capricorn Venture Partners in March 1998 Marc served for six years as Senior Scientific Adviser at IWT and worked two years at the European R&D lab of Terumo Europe NV. Marc has a PhD in Electrical Engineering of the University of Leuven, more specifically on implantable biosensors.

Matthieu is a visionary entrepreneur with great people management and communication skills. Under his leadership FEops has transformed from a small academic spin-off into a fast-growing venture capital backed gazelle in the medtech sector. He completed his degree in Engineering at the University of Ghent in 2002 and gained his PhD in 2008 for his research on cardiovascular device and procedure modeling. In 2009 he followed the general management program ‘Technology Transfer’ at Vlerick Leuven Gent Management School. Matthieu is author of several high-impact scientific publications.

Guillaume is Investment Manager at Valiance, a London based investment firm. Guillaume is responsible for its portfolio of Life Sciences companies, investing growth capital into innovative medical technologies in Europe and in the US. Prior to that, Guillaume has a career in Investment Banking, advising large capitalization corporates on Mergers and Acquisitions and other corporate finance decisions including Capital Markets financing. Guillaume has experience in various sectors including Healthcare but also Consumer, Retail, Telecoms, e-Commerce, Oil & Gas. He graduated from ESSEC Business School in Paris.

Worked twenty-one years with Boston Scientific Corporation, in the most recent role as Vice President and General Manager, Transcatheter Aortic Valves (TAVR) from 2012 - 2017, was responsible for leading Boston Scientific into the global market for minimally invasive Transcather Aortic Valves and was intimately involved with the New Business Development Strategy for structural heart. He holds a B.S. Business Degree from the University of Minnesota, Minneapolis with concentration in Marketing and Logistics


FEops is a fast growing company developing cutting edge simulation technology for next generation planning of transcatheter structural heart interventions.

If you are looking forward to help us grow together with you, please do not hesitate and send your motivation letter and CV to

Apply Here

Now looking for

We welcome spontaneous applications for internships or a (future) position / vacancies to strengthen our R&D, operational and commercial activities.

News & Events

  • 25 10 2018

    2018 International Conference for Computational Science and Clinical Applications (iC3) (Shanghai, October 25-27)

    On Friday October 26, our CEO Matthieu De Beule will hold a lecture about 'Patient-based computational modelling and simulation for structural heart interventions'

  • 29 10 2018

    European Congress on eCardiology and eHealth (Moskow, October 29-30)

    Looking forward to being in Moscow where Patricio Astudillo will share his insights on how to use artificial intelligence to automate TAVI device size selection.

  • 17 11 2018

    CSI - LAA (Frankfurt, 17 - 18 Nov)

    Early experience with computational modelling and simulation in order to optimise LAA closure outcomes. Meet us during Session 1, 08.00 - 10.20 AM Imaging the LAA: Tools and techniques tips and tricks.
    Presentation of Ole De Backer, MD, PhD, 10.03 - 10.11 AM Imaging the LAA: Tools and techniques tips and tricks.

  • 02 12 2018

    ICI Meeting 2018, December 2-4 Tel Aviv

    Meet us at the Technology Parade where we will show how FEops HEARTguide™ surpasses basic anatomical measurement, generating accurate predictions of how devices will interact with each unique patient.


While it is vital to have quantitative information on the targeted cardiovascular anatomy when developing a new medical device, it is often difficult to find detailed information on the geometry of the anatomies (average values and standard deviations of diameters, amount of tapering, angles, etc.)

FEops has developed unique tools to perform automated measurements on 3D anatomical reconstructions (e.g. CT- or MRI-based), which allow the data of a large number of patients to be analyzed within a reasonable period. Through our clinical network, we can assist companies in finding appropriate medical image data.

your concept

New device ideas can be evaluated by manufacturing prototypes and subsequent bench testing. Regularly this is time-consuming and not always cost-efficient. Alternatively, computer simulations can be used for this purpose reducing the amount of prototypes to be built and speeding-up the design cycle.

Due to our extensive experience with intravascular devices, we rapidly understand new device concepts. We offer the most advanced simulations, in which the interaction of the new device with a realistic vascular model can be investigated, giving extremely valuable insights into the device behaviour. Based on these realistic simulations, figures and animations can be created that can help start-up companies to attract investors.

& development

During the early phases of the design cycle it is not a sinecure to select the most promising device design alternative to further optimize. Computer simulations can help with this selection and reduce the number of prototypes to be built and thus speed up the design cycle significantly.

Thanks to its extensive experience with intravascular devices, FEops provides developers with advanced computer simulations to evaluate new device performance (e.g. radial strength, flexibility, crimpability, deployment behavior, etc.). The simulations help to explore different design alternatives without having to manufacture prototypes. With these virtual bench tests, we can also perform a virtual Design Of Experiments (DOE) and determine the optimal device design.

computer simulation

Merging simulation technologies with medical imaging opens the door to patient-tailored therapy.

FEops provides unique simulation technology to implant intravascular devices within patient-based models and to visualize the interaction of the new device with a realistic vascular model. The technology allows medical device manufacturers to evaluate new devices in multiple patient-based anatomical models prior or in parallel to conducting expensive and risky animal or clinical trials or to gain insights into device behavior during a clinical trial.


Accelerated in-vitro fatigue testing is expensive and time-consuming. Finite element simulations can help to reduce the amount of real fatigue tests to a minimum, as it can be used to detect the worst-case device size and loading conditions.

FEops performs accurate stress / strain analyses to determine fatigue safety factors following ISO Standards (e.g. ISO 25539) and FDA guidelines. This information is then used to perform a limited number of accelerated in-vitro fatigue tests.

& education

Illustrating the functioning and benefits of a device is crucial for successful marketing, but also to educate people on the device characteristics and its use.

FEops’ advanced computer models can be used to generate realistic animations and high-quality images of medical devices, used for marketing and educational services. Moreover, start-up companies can use our computer simulations as a basis for figures and animations that can help attract investors. FEops is experienced in reverse engineering products (i.e. building models starting from a device sample). In this way, we can compare new technologies with existing products on the market.